Nephrosclerosis
Conditions
Interventions
After observation period for 4 weeks with 20mg of olmesartan, participants were randomly assigned to a group treated with 40mg of olmesartan for 52 weeks.
After observation period for 4 weeks with 20
Sponsors
Department of Nephrology, University of Tsukuba.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Participants who gave written informed consent. (2) Outpatients (3)Systolic blood pressure at clinic is more than 140 mmHg or diastolic pressure is more than 90 mmHg (4)Serum HbA1c concentration is less than 6.0 (5)urinary albumin excretion is less than 1g/g.Cr. (6)Patients treated with RAS-inhibitor but not with Ca channel blocker for 2 months just before initiation of the study.
Exclusion criteria
Exclusion criteria: 1. Hypertensive crisis 2. Hyperkalemia (serum potassium conc.>5.5mM) 3. renal failure (eGFR<30ml/min/1.73m2) 4. bilateral renal artery stenosis 5. newly onset of stroke (within 6 months just before entry) 6. severe congestive heart failure (more than NYHA class III) 7. liver dysfunction (AST/ALT concentration is 5 fold higher than normal range) 8. newly onset of acute myocardial infarction. 9. Malignancy 10. Patients who had severe adverse reactions by Ca channel blockers of RAS inhibitors. 11. Patients who are prescribed immunosuppressant or glucocorticoids. 12. Patients who are prescribed NSAIDs for long time (more than 2 weeks). 13. Patients whose doctors determined as inadequate for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of estimated GFR before and after the treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of following paparemters before and after the treatment (1) 1/serum creatinine concetration (2) Office blood pressure (3) heart rate (4) urinary albumin excretion (5) serum concentrations of BUN, cystatin C, and hs-CRP. | — |
Countries
Japan
Contacts
Public ContactChie Saito
University of Tsukuba Nephrology
Outcome results
None listed